Role of gut microbiota in doxorubicin-induced cardiotoxicity: from pathogenesis to related interventions

Chao Huang,Xiaoxia Li,Hanqing Li,Ruolan Chen,Zhaoqing Li,Daisong Li,Xiaojian Xu,Guoliang Zhang,Luning Qin,Bing Li,Xian-Ming Chu
DOI: https://doi.org/10.1186/s12967-024-05232-5
2024-05-08
Abstract:Doxorubicin (DOX) is a broad-spectrum and highly efficient anticancer agent, but its clinical implication is limited by lethal cardiotoxicity. Growing evidences have shown that alterations in intestinal microbial composition and function, namely dysbiosis, are closely linked to the progression of DOX-induced cardiotoxicity (DIC) through regulating the gut-microbiota-heart (GMH) axis. The role of gut microbiota and its metabolites in DIC, however, is largely unelucidated. Our review will focus on the potential mechanism between gut microbiota dysbiosis and DIC, so as to provide novel insights into the pathophysiology of DIC. Furthermore, we summarize the underlying interventions of microbial-targeted therapeutics in DIC, encompassing dietary interventions, fecal microbiota transplantation (FMT), probiotics, antibiotics, and natural phytochemicals. Given the emergence of microbial investigation in DIC, finally we aim to point out a novel direction for future research and clinical intervention of DIC, which may be helpful for the DIC patients.
What problem does this paper attempt to address?